Spero Therapeutics, Inc. (SPRO): who owns it and who trades it
As of Nov 16, 2026, SPRO insiders reported 9 open-market sales worth $499K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Esther Rajavelu (See Remarks), with $354K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Spero Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SPRO
61 funds and institutions reported SPRO shares worth $47.6M at the end of Q2 2026, about 37% of the company. The largest holder is GSK plc with 15.9%.
Funds and institutions (13F) 37%Everyone else 63%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| GSK plc | 9.19M | 15.88% | $20.3M | No change |
| Pfizer Inc | 2.36M | 4.08% | $5.3M | No change |
| Vanguard Capital Management LLC | 2.04M | 3.52% | $4.5M | +13% |
| Renaissance Technologies LLC | 947,904 | 1.64% | $2.1M | -20% |
| Alphabet Inc. | 889,979 | 1.54% | $2M | No change |
| Susquehanna International Group, LLP | 759,290 | 1.31% | $1.7M | +128% |
| BlackRock, Inc. | 594,404 | 1.03% | $1.3M | +37% |
| Geode Capital Management, LLC | 566,329 | 0.98% | $1.3M | +9% |
| Raymond James Financial Inc | 521,705 | 0.90% | $1.2M | New |
| Two Sigma Investments, LP | 382,814 | 0.66% | $846K | -57% |
| Arrowstreet Capital, Limited Partnership | 332,970 | 0.58% | $736K | New |
| Vanguard Fiduciary Trust Co | 287,648 | 0.50% | $636K | +9% |
| Gsa Capital Partners LLP | 285,906 | 0.49% | $632K | +3% |
| Dimensional Fund Advisors LP | 274,820 | 0.47% | $608K | +823% |
| Goldman Sachs Group Inc | 256,985 | 0.44% | $568K | New |
| State Street Corp | 214,751 | 0.37% | $475K | No change |
| Jane Street Group, LLC | 158,097 | 0.27% | $349K | +49% |
| UBS Group AG | 139,680 | 0.24% | $309K | +4542% |
| Bridgeway Capital Management, LLC | 114,800 | 0.20% | $254K | No change |
| Northern Trust Corp | 108,274 | 0.19% | $239K | -11% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, SPRO insiders reported $0 of open-market purchases and $499K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Esther Rajavelu | Director | Sale | 40,851 | $1.04 | $42.5K | Form 4 |
| May 4, 2026 | Esther Rajavelu | See Remarks | Sale | 25,240 | $2.51 | $63.4K | Form 4 |
| Feb 6, 2026 | Esther Rajavelu | See Remarks | Sale | 37,101 | $2.36 | $87.6K | Form 4 |
| Feb 6, 2026 | Esther Rajavelu | See Remarks | Sale | 50,816 | $2.36 | $120K | Form 4 |
| Feb 6, 2026 | Timothy Keutzer | Chief Operating Officer | Sale | 18,652 | $2.36 | $44K | Form 4 |
| Feb 4, 2026 | Timothy Keutzer | Chief Operating Officer | Sale | 3,471 | $2.24 | $7.8K | Form 4 |
| Feb 3, 2026 | Timothy Keutzer | Chief Operating Officer | Sale | 24,224 | $2.14 | $51.8K | Form 4 |
| Feb 2, 2026 | Timothy Keutzer | Chief Operating Officer | Sale | 18,891 | $2.20 | $41.6K | Form 4 |
| Feb 2, 2026 | Esther Rajavelu | See Remarks | Sale | 18,442 | $2.20 | $40.6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Esther Rajavelu | See Remarks | – | $354K | Nov 9, 2026 |
| Timothy Keutzer | Chief Operating Officer | – | $145K | Feb 6, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SPRO short interest
Low short interest. 1.4% of SPRO shares are sold short: about 1 share in 74. Over the last 12 reports the number of shares short went down 52%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 787,025 SPRO shares were sold short, 1.4% of the shares outstanding, down 6.4% from the report before. At the average daily volume of 353,093 shares, buying them all back would take about 2.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 787,025 | 1.35% | -6% | 353,093 | 2.2 |
| Oct 15, 2026 | 840,529 | 1.44% | +6% | 558,471 | 1.5 |
| Sep 30, 2026 | 794,509 | 1.36% | -19% | 1.14M | 1.0 |
| Sep 15, 2026 | 976,488 | 1.68% | -19% | 319,458 | 3.1 |
| Aug 31, 2026 | 1.21M | 2.08% | -16% | 409,813 | 3.0 |
| Aug 14, 2026 | 1.45M | 2.48% | -4% | 760,511 | 1.9 |
| Jul 31, 2026 | 1.51M | 2.61% | -28% | 2.52M | 1.0 |
| Jul 15, 2026 | 2.11M | 3.65% | -26% | 1.65M | 1.3 |
| Jun 30, 2026 | 2.86M | 4.95% | +56% | 2.75M | 1.0 |
| Jun 15, 2026 | 1.83M | 3.16% | +7% | 813,375 | 2.2 |
| May 29, 2026 | 1.71M | 2.95% | +4% | 868,868 | 2.0 |
| May 15, 2026 | 1.65M | 2.85% | +40% | 630,469 | 2.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Spero Therapeutics company events
Spero Therapeutics filed 11 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026LeadershipPatrick Vink, M.D., who was serving as a Class II director, notified the Board of Directors of Spero Therapeutics, Inc., of his decision to resign as a member of the Board, including from his role as the Chair of the Nominating and Corporate Governance Committee, a member of the Compensation… Filing
- Oct 27, 2026LeadershipSpero Therapeutics, Inc. announced that Timothy Keutzer, the Company’s Chief Operating Officer, will retire from the Company effective as of December 31, 2026. Filing
- Aug 28, 2026AgreementSpero Therapeutics, Inc., a Delaware corporation, entered into an Open Market Sale Agreement℠ with Jefferies LLC, as agent, pursuant to which the Company may offer and sell shares of its common stock, $0.001 par value per share, from time to time through Jefferies. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jul 14, 2026AgreementSpero Therapeutics, Inc. entered into a license agreement with Innovent Biologics (Suzhou) Co., Ltd. and Fortvita Biologics (USA), Inc. (collectively, “Innovent”), pursuant to which Innovent granted the Company an exclusive (even as to Innovent and its affiliates, subject to Innovent’s right to… Filing
- Jun 25, 2026LeadershipApproval of the 2026 Stock Incentive Plan At the 2026 Annual Meeting of Stockholders of Spero Therapeutics, Inc. held on June 23, 2026, the Company’s stockholders approved the Spero Therapeutics, Inc. 2026 Stock Incentive Plan, which had previously been adopted by the Company’s board of directors… Filing
- Jun 22, 2026AnnouncementThe Company issued a press release announcing that the FDA has granted approval for Utebzi (tebipenem pivoxil), an oral antibiotic for the treatment of cUTIs, including pyelonephritis, caused by certain susceptible pathogens in adult patients who have limited or no alternative oral treatment option. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Jan 30, 2026LeadershipAnkit Mahadevia, MD notified the Board of Directors of Spero Therapeutics, Inc. of his intention to resign from the Board, including from his service on the Development Committee of the Board and from all officer and director positions he holds with any and all subsidiaries of the Company… Filing
- Dec 19, 2025AnnouncementSpero Therapeutics, Inc. announced that its tebipenem HBr development partner, GlaxoSmithKline Intellectual Property (No. 3) Limited, filed a New Drug Application resubmission to the U.S. Food and Drug Administration for tebipenem HBr, an investigational oral carbapenem antibiotic being developed… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Spero Therapeutics financials
Famous investors that hold SPRO
3 of the 50 well-known investors we track reported holding SPRO in their latest 13F filing. The largest position is Jim Simons's, worth $1.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.41M | $1.7M | 0.0% | +49% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 725,988 | $878K | 0.0% | New |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 14,639 | $17.7K | 0.0% | -86% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Spero Therapeutics, Inc. (SPRO) stock
Who owns the most SPRO stock?
The largest reported owner of Spero Therapeutics, Inc. (SPRO) is GSK plc, with 15.9% of the company. In total, 61 funds and institutions reported holding SPRO at the end of Q2 2026, together about 37% of the shares. See the largest owners.
Are SPRO insiders buying or selling?
In the last 12 months, SPRO insiders reported no open-market purchases and 9 sales worth $499K. The latest trade was on Nov 9, 2026. See every trade.
What is the short interest in SPRO?
As of Oct 30, 2026, 787,025 SPRO shares were sold short, 1.4% of the shares outstanding, down 6.4% from the report before. At the average daily volume of 353,093 shares, buying them all back would take about 2.2 trading days (days to cover). See the history.
Which famous investors hold SPRO?
3 of the 50 well-known investors we track reported SPRO in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $1.7M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.